UAE Oral Wegovy Approval Turns Weight-Loss Demand Into a Clinical Discipline Test
The Emirates Drug Establishment approved Wegovy as an oral semaglutide tablet for long-term weight management in adults in the UAE. The UAE is only the second country after the United States to approve and receive supply of the once-daily pill, with doctors citing around 17 percent weight loss over about a year for patients who stayed on treatment. The practical test is whether easier access through a pill format remains tied to clinical screening, diet and physical activity rather than short-term cosmetic use.
UAE Approval Moves Wegovy From Injection Debate to Daily-Pill Discipline
The Emirates Drug Establishment has approved Wegovy as an oral semaglutide tablet for long-term weight management in adults, making the UAE only the second country after the United States to approve and receive supply of the once-daily pill.
The approval covers adults with obesity or people who are overweight with at least one weight-related comorbidity, and it includes a cardiovascular-risk mandate for high-risk patients.
The change is not only about replacing a weekly injection with a tablet.
Dr Ihsan Almarzooqi, co-founder and managing director of Metabolic, said the same molecule is being delivered through a different route.
"It is not a different or weaker drug," he said.
"The only difference is how it gets into the body."
Convenience comes with a strict routine.
Almarzooqi said the tablet must be taken first thing in the morning on an empty stomach with water, with patients waiting before eating or drinking because absorption is highly sensitive.
He said trial results showed weight loss in the same range as the injection, around 17 percent over about a year for people who stayed on treatment.
A Consumer-Health Signal, Not a Shortcut
The commercial signal for the UAE health market is that weight-management treatment is becoming easier to access, but more dependent on patient discipline and clinical screening.
Almarzooqi said the right candidates are adults living with obesity or overweight patients with conditions such as Type 2 diabetes, hypertension or cardiovascular risk.
He drew a clear line around aesthetic use.
Almarzooqi said people at a normal BMI seeking a cosmetic result should not be treated with the medicine.
"That is not what this medicine is for," he said.
That warning matters for clinics, insurers and pharmacies because a pill format could broaden demand beyond patients who previously avoided injections.
The approval may remove barriers such as needles, refrigeration and travel logistics, but it does not remove the need for medical judgment.
Cardiovascular Risk Becomes Part of the Market Test
Dr Ahmed Sharafeldin, consultant interventional cardiologist at RAK Hospital, said the approval changes the discussion from appearance to health outcomes.
The Emirates Drug Establishment approval highlights the pill's ability to reduce major adverse cardiovascular events, including heart attacks and strokes, in high-risk populations.
"We are no longer talking about weight loss solely as a cosmetic outcome," Sharafeldin said.
He added that effective obesity treatment can contribute to reducing cardiovascular risk by improving factors such as blood pressure, cholesterol and diabetes control.
Sharafeldin also cautioned that the medicine is approved for use alongside a reduced-calorie diet and increased physical activity.
The practical test is whether daily-pill convenience leads to supervised, sustained treatment rather than casual use by people seeking fast cosmetic weight loss.
